Leukemia

A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

Publication Date	April 2009
Publisher	Bioseeker
Product Type	Report
Pages	512
ISBN Number	not applicable
Product Code	BSK00072

Buy this product or for assistance call +44 20 7060 7474

PDF £1,740.00$2894 | €1947

FAX Order above formats by FAX

Summary

This report includes defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products.

It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

Providing competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
Providing commercial analytic support for due diligence on in-licensing and acquisition opportunities

This report will also be an important part of creating and implementing a market development plan for any leukemia drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

BioSeeker's leukemia pipeline evaluation of development options, competitive landscape and positioning is derived through extensive pipeline benchmarking analysis, including:

Single Drug Target Analysis of 136 Drug Targets

Highlighting twelve themes about the drug target (i.e. Drugs and investigators sharing a particular target, Types of compounds aimed at a specific target, Protein-protein interactions of a specific target with other known leukemia drug targets, Pathway involvement of a drug target, Presence of structural and protein expression data of a target etc.)
Supportive chapters on selected drug themes above

Competitive Landscape Analysis based on 115 Identified Drug Target Combinations

Identifies New and Unique leukemia drugs by developmental stage
Head-to-head targeting competition
Targeting competition by at least 50% bi-directional drug target combination match
Clinical validation and progress on all identified drug target combinations

Competitive Landscape Analysis based on Compound Strategies at Work

Identifies New and Unique leukemia drugs based on six different compound strategies (Small molecules, Peptide/Protein, Antibody, Nucleic acid therapies, Gene therapy and Reformulation drugs)
Head-to-head targeting competition
Targeting competition by at least 50% bi-directional drug target combination match Competitive Benchmarking of Leukemia Pipeline by 126 Investigators
Competitive Fall-out table for each of the included investigators' leukemia pipeline, overlaid with head-to-head targeting competitors' drugs
Competitive summary profile for each one of the 175 included leukemia drugs

Content

1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 Table of Contents
- 4.1 List of Figures
- 4.2 List of Tables
5 Introduction
6 Single Drug Target Benchmarking from the Leukemia Pipeline
- 6.1.1 Carboxy-Lyase Activity Targets
- 6.1.2 Catalytic Activity Targets
- 6.1.3 Cell Adhesion Molecule Activity Targets
- 6.1.4 Chaperone Activity Targets
- 6.1.5 Cysteine-Type Peptidase Activity Targets
- 6.1.6 Cytokine Activity Targets
- 6.1.7 Deaminase Activity Targets
- 6.1.8 DNA Repair Protein Targets
- 6.1.9 DNA Topoisomerase Activity Targets
- 6.1.10 DNA-Directed DNA Polymerase Activity Targets
- 6.1.11 DNA-Methyltransferase Activity Targets
- 6.1.12 G-Protein Coupled Receptor Activity Targets
- 6.1.13 Growth Factor Activity Targets
- 6.1.14 Hydrolase Activity Targets
- 6.1.15 Kinase Activity Targets
- 6.1.16 Kinase Regulator Activity Targets
- 6.1.17 Ligand-Dependent Nuclear Receptor Activity Targets
- 6.1.18 Ligase Activity Targets
- 6.1.19 Lipid Kinase Activity Targets
- 6.1.20 MHC Class I Receptor Activity Targets
- 6.1.21 Molecular Function Unknown Targets
- 6.1.22 Motor Activity Targets
- 6.1.23 Oxidoreductase activity Targets
- 6.1.24 Phosphoric diester hydrolase activity Targets
- 6.1.25 Phosphorylase activity Targets
- 6.1.26 Protein Binding Targets
- 6.1.27 Protein serine/threonine kinase activity Targets
- 6.1.28 Protein tyrosine phosphatase activity Targets
- 6.1.29 Protein-tyrosine kinase activity Targets
- 6.1.30 Receptor Activity Targets
- 6.1.31 Receptor Signaling Complex Scaffold Activity Targets
- 6.1.32 RNA Binding Targets
- 6.1.33 RNA-Directed DNA Polymerase Activity Targets
- 6.1.34 Serine-Type Peptidase Activity Targets
- 6.1.35 Structural Constituent Of Cytoskeleton Targets
- 6.1.36 Superoxide dismutase activity Targets
- 6.1.37 T Cell Receptor Activity Targets
- 6.1.38 Transcription Factor Activity Targets
- 6.1.39 Transcription Regulator Activity Targets
- 6.1.40 Transferase Activity Targets
- 6.1.41 Translation Regulator Activity Targets
- 6.1.42 Transmembrane receptor activity Targets
- 6.1.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
- 6.1.44 Transporter activity Targets
- 6.1.45 Other Targets
6.2 The Cancer Genome Project and Leukemia Targets
- 6.2.1 Leukemia Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.3 Structure-based Drug Design in Leukemia is Stimulated by Available Structure Data on Biological Targets
6.4 Target-Target Interactions among Identified Leukemia Targets
6.5 The Drug-Target Interactome
6.6 Protein Expression Levels of Identified Drug Targets of Leukemia Drugs
6.7 Pathway Analysis of Leukemia Drug Targets
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Combinations Identified in the Leukemia Pipeline?
7.1 Pre-Registration to being Marketed: New and Unique Drug Target Combinations of the Leukemia Pipeline
7.2 Phase III Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline
7.3 Phase II Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline
7.4 Phase I Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline
7.5 Preclinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline
7.6 Development Profiles of All Leukemia Drug Target Combinations
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Pipeline by Type of Compound
8.1 Small Molecules
- 8.1.1 Background
- 8.1.2 Targets in Leukemia
8.2 Peptide/Protein Drugs
- 8.2.1 Background
- 8.2.2 Targets in Leukemia
8.3 Antibodies and Antibody-like Structures
- 8.3.1 Background
- 8.3.2 Targets in Leukemia
8.4 Nucleic Acid Therapies
- 8.4.1 Background
- 8.4.2 Targets in Leukemia
8.5 Gene Therapy
- 8.5.1 Background
- 8.5.2 Targets in Leukemia
8.6 Drug Delivery and Nanotechnology
- 8.6.1 Background
- 8.6.2 Targets in Leukemia
8.7 Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets
9 Portfolio Planning: Competitive Benchmarking of Leukemia Pipeline by Investigator
9.1 4SC
9.2 Abbott
9.3 Abiogen
9.4 Actinium Pharmaceuticals
9.5 AEgera
9.6 Aeterna Zentaris
9.7 Agennix
9.8 Alexion
9.9 Alfa Wassermann
9.10 Ambit Biosciences
9.11 Amgen
9.12 Antigenics
9.13 Antisoma
9.14 Ariad
9.15 Arno Therapeutics
9.16 Array BioPharma
9.17 Asahi Kasei Pharma
9.18 Ascenta Therapeutics
9.19 Astellas
9.20 Astex Therapeutics
9.21 AstraZeneca
9.22 Attenuon
9.23 Bayer
9.24 BioCryst Pharmaceuticals
9.25 Biogen Idec
9.26 Bioton
9.27 Boehringer Ingelheim
9.28 Bristol-Myers Squibb
9.29 BTG
9.30 Calistoga Pharmaceuticals
9.31 Callisto Pharmaceuticals
9.32 Celator Pharmaceuticals
9.33 Cell Genesys
9.34 Cell Therapeutics
9.35 Cephalon
9.36 CJ Corp
9.37 Clavis Pharma
9.38 Curacyte
9.39 Cyclacel
9.40 Cylene Pharmaceuticals
9.41 CytImmune Sciences
9.42 Cytokinetics
9.43 Daiichi Sankyo
9.44 Dainippon Sumitomo Pharma
9.45 Dara Biosciences
9.46 Deciphera Pharmaceuticals
9.47 Dong-A
9.48 Eleos
9.49 Eli Lilly
9.50 Enzon
9.51 EpiCept
9.52 Exelixis
9.53 ExonHit Therapeutics
9.54 Gemin X Pharmaceuticals
9.55 Genentech
9.56 Genmab
9.57 Genta
9.58 Genzyme
9.59 Geron
9.60 GlaxoSmithKline
9.61 Gloucester Pharmaceuticals
9.62 GlycoGenesys
9.63 Hayashibara
9.64 Hoffmann-La Roche
9.65 ImClone Systems
9.66 Immunomedics
9.67 Innate Pharma
9.68 Innovive
9.69 Isis Pharmaceuticals
9.70 Italfarmaco
9.71 Johnson & Johnson
9.72 Kanisa
9.73 Kyowa Hakko Kirin
9.74 LG Life Sciences
9.75 Lorus Therapeutics
9.76 MAT Biopharma
9.77 MaxCyte
9.78 Meda
9.79 Medarex
9.80 MethylGene
9.81 Micromet
9.82 MorphoSys
9.83 NanoMed Pharmaceuticals
9.84 Nerviano Medical Sciences
9.85 National Institute of Health (USA)
9.86 Nippon Shinyaku
9.87 Novartis
9.88 Novogen
9.89 PDL BioPharma
9.90 Peplin
9.91 Pfizer
9.92 Pharmacyclics
9.93 PharmaMar
9.94 PIERIS Proteolab
9.95 Rigel
9.96 Sanofi-Aventis
9.97 Santaris Pharma
9.98 SBIO
9.99 Schering-Plough
9.100 SciGen
9.101 Seattle Genetics
9.102 Sepal Pharma
9.103 Servier
9.104 Shantha Biotechnics
9.105 Sidus
9.106 Spirogen
9.107 Stemline Therapeutics
9.108 SuperGen
9.109 Supratek Pharma
9.110 Swedish Orphan
9.111 SymBio Pharmaceuticals
9.112 Takeda
9.113 Teva
9.114 TopoTarget
9.115 Trion Pharma
9.116 Trubion
9.117 Vertex Pharmaceuticals
9.118 Vion Pharmaceuticals
9.119 VioQuest
9.120 Wyeth
9.121 Yamasa Corporation
9.122 Zenyaku Kogyo
9.123 ZymoGenetics
9.124 Non-Industrial Sources
10 Disclaimer
11 Drug Index
12 Company Index
4.1 List of Figures
Figure 1: Overall Breakdown of Included Leukemia Pipeline by Sub-indication and Stage of Development
Figure 2: Visualization of Target-Target Interactions Among Leukemia Drug Targets
Figure 3: The Drug-Protein Interactome of Leukemia Drugs The Main Cluster
Figure 4: The Drug-Protein Interactome of Leukemia Drugs Smaller Clusters
Figure 5: Head-to-Head Targeting Interactome of Leukemia Drugs
Figure 6: Distribution of Compound Types among Leukemia Drugs
Figure 7: Primary Sub-cellular Localization of Drug Targets
4.2 List of Tables
Table 1: Overview of Drug Target Profile Themes
Table 2: Drug Targets of Leukemia Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Identity of Leukemia Drug Targets with Available Biological Structures
Table 4: Number of Target-Target Interactions among Leukemia Drug Targets
Table 5: Drug-Protein Interactome Clusters
Table 6: Leukemia Drug Targets with Available Protein Expression Profiles
Table 7: Pathway Summary
Table 8: Drug Targets without any Identified Assigned Pathways
Table 9: Pathway Profile According to BioCarta of Leukemia Drug Targets
Table 10: Pathway Profile According to KEGG of Leukemia Drug Targets
Table 11: Pathway Profile According to NetPath of Leukemia Drug Targets
Table 12: Number of Drug Target Combinations by the Highest Developmental Stage and Uniqueness
Table 13: Top 5 Competitive Leukemia Targets
Table 14 New and Unique Leukemia Targets in Pre-Registration to Marketed
Table 15: New and Unique Leukemia Targets in Phase III Clinical Development
Table 16: New and Unique Leukemia Targets in Phase II Clinical Development
Table 17 New and Unique Leukemia Targets in Phase I Clinical Development
Table 18: New and Unique Leukemia Targets in Preclinical Development
Table 19: The Progression, Maturity and Competitive Comparison of Leukemia Drug Target Combinations in Development
Table 20: Number of Leukemia Drug Target Mixes Reported by Compound Strategy
Table 21: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Leukemia by Drug Target
Table 22: Drug Targets of Small Molecule Drugs in Leukemia
Table 23: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Leukemia
Table 24: Drug Targets of Peptide Based Drugs in Leukemia
Table 25: Drug Targets of Protein Based Drugs in Leukemia
Table 26: Drug Targets of Antibodies and Antibody-like Drugs in Leukemia
Table 27: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Leukemia
Table 28: Drug Targets of Nucleic Acid Therapies in Leukemia
Table 29: Vectors in Gene Therapy
Table 30: Drug Targets of Gene Therapies in Leukemia
Table 31: Drug Targets with New Drug Delivery Strategies in Leukemia
Table 32: Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets
Table 33: 4SC's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 34: Abbott's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 35: Abiogen's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 36: Actinium Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 37: AEgera's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 38: Aeterna Zentaris' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 39: Agennix's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 40: Alexion's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 41: Alfa Wassermann's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 42: Ambit Biosciences' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 43: Amgen's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 44: Antigenics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 45: Antisoma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 46: Ariad's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 47: Arno Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 48: Array BioPharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 49: Asahi Kasei Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 50: Ascenta Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 51: Astellas' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 52: Astex Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 53: AstraZeneca's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 54: Attenuon's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 55: Bayer's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 56: BioCryst Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 57: Biogen Idec's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 58: Bioton's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 59: Bioton's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 60: Bristol-Myers Squibb's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 61: BTG's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 62: Calistoga Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 63: Callisto Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 64: Celator Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 65: Cell Genesys' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 66: Cell Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 67: Cephalon's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 68: CJ Corp's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 69: Clavis Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 70: Curacyte's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 71: Cyclacel's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 72: Cylene Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 73: CytImmune Sciences' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 74: Cytokinetics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 75: Daiichi Sankyo's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 76: Dainippon Sumitomo Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 77: Dara Biosciences' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 78: Deciphera Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 79: Dong-A's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 80: Eleos' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 81: Eli Lilly's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 82: Enzon's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 83: EpiCept's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 84: Exelixis' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 85: ExonHit Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 86: Gemin X Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 87: Genentech's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 88: Genmab's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 89: Genta's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 90: Genzyme's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 91: Geron's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 92: GlaxoSmithKline's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 93: Gloucester Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 94: GlycoGenesys' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 95: Hayashibara's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 96: Hoffmann-La Roche's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 97: ImClone Systems' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 98: Immunomedics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 99: Innate Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 100: Innovive's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 101: Isis Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 102: Italfarmaco's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 103: Johnson & Johnson's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 104: Kanisa's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 105: Kyowa Hakko Kirin's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 106: LG Life Sciences' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 107: Lorus Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 108: MAT Biopharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 109: MaxCyte's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 110: Meda's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 111: Medarex's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 112: MethylGene's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 113: Micromet's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 114: MorphoSys' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 115: NanoMed Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 116: Nerviano Medical Sciences' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 117: NIH's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 118: Nippon Shinyaku's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 119: Novartis' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 120: Novogen's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 121: PDL BioPharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 122: Peplin's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 123: Pfizer's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 124: Pharmacyclics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 125: PharmaMar's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 126: PIERIS Proteolab's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 127: Rigel's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 128: Sanofi-Aventis' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 129: Santaris Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 130: SBIO's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 131: Schering-Plough's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 132: SciGen's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 133: Seattle Genetics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 134: Sepal Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 135: Servier's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 136: Shantha Biotechnics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 137: Sidus' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 138: Spirogen's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 139: Stemline Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 140: SuperGen's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 141: Supratek Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 142: Swedish Orphan's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 143: SymBio Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 144: Takeda's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 145: Teva's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 146: TopoTarget's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 147: Trion Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 148: Trubion's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 149: Vertex Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 150: Vion Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 151: VioQuest's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 152: Wyeth's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 153: Yamasa Corporation's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 154: Zenyaku Kogyo's Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 155: ZymoGenetics' Included Leukemia Pipeline Composition and Competitive Fall-Out
Table 156: Non-industrial Sources' Included Leukemia Pipeline Composition and Competitive Fall-Out